Fluticasone propionate nasal spray

Generic name
Fluticasone propionate nasal spray
Brand name
ATC Code
R01AD08
Compare …

Fluticasone propionate nasal spray

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Allergic rhinitis
  • Nasal
    • 4 years up to 12 years
      • In each nostril 1 puff(s)/dose 1-2x daily.. Start with once daily; increase to twice daily if the symptoms are insufficiently controlled..

      • administer in the mornings

    • 12 years up to 18 years
      • In each nostril 2 puff(s)/dose 1-2x daily.. Start with once daily; increase to twice daily if the symptoms are insufficiently controlled..

      • administer in the mornings

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Growth retardation.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Growth inhibition has been reported in children when therapeutic doses are used; in long-term use, especially with combined inhalation therapy for asthma, check the growth and if there is growth inhibition attempt to reduce the dose and refer to the paediatrician. The lowest possible dose must be used in children if long-term use of nasal corticosteroids in children is necessary.

Following systemic effects are possible, especially in children after using higher doses over a longer period of time: mental or behavioral changes, including psychomotor hyperactivity, insomnia, anxiety, depression, or aggression (SmPC). 

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Sympathomimetics, plain
R01AA08
R01AA05
R01AA09
R01AA07
Sympathomimetics, combinations excl. corticosteroids
R01AB01
Antiallergic agents, excl. corticosteroids
R01AC03
R01AC01
R01AC02
Corticosteroids
R01AD58
R01AD01
R01AD05
R01AD12
R01AD12
R01AD09
R01AD59
R01AD11
Other nasal preparations
R01AX10
OTHER NASAL PREPARATIONS
R01AX10

Reference

  1. GlaxoSmithKline BV, SPC Flixonase (RVG 14424), www.cbg-meb.nl, Geraadpleegd 27 mei 2010, http://db.cbg-meb.nl/IB-teksten/h14424.pdf

Changes

Therapeutic Drug Monitoring


Overdose